REG - Sareum Holdings PLC - Appointment of Joint Broker

Sareum HoldingsAnnouncement

18/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241218:nRSR4779Qa&default-theme=true

RNS Number : 4779Q  Sareum Holdings PLC  18 December 2024

Sareum Holdings plc

("Sareum" or the "Company")

Appointment of Joint Broker

Cambridge, UK, 18 December 2024 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, is pleased to announce the
appointment of Oberon Capital as a Joint Corporate Broker with immediate
effect.  Oberon Capital is a trading name of Oberon Investments Limited.

Strand Hanson Limited and Hybridan LLP will continue to act as the
Company's Nominated Adviser and Joint Corporate Broker, respectively.

- Ends -

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chairman               01223 497700

                                                  ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                      020 7409 3494

 Oberon Capital (Joint Broker)

 Mike Seabrook / Nick Lovering                    020 3179 5300

 Hybridan LLP (Joint Broker)

 Claire Noyce                                     020 3764 2341

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi / Kumail Waljee   0203 709 5700

 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has completed
Phase 1 clinical development and is readying for phase 2 trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFZMMZNNDGDZM